

EXPRESSION OF INTEREST STAGE

An Expression of Interest (EOI) form comes to R&D Governance team via team leader, the Clinical Research Network (CRN), the Clinical Research Facility (CRF) or from the Sponsor / CRO to R&D Enquiries inbox (papworth.randdenquiries@nhs.net)

R&D Governance team review EOI for patient cohort and potential impact.

Specialty not relevant to Trust; decline

Team Leader & / consultant contacted by R&D team to assess capacity and initial feasibility for study.

No capacity; decline EOI.

EOI is responded to & sent back Sponsor /CRO. Site is sent a Confidential Disclosure Agreement (CDA) (if applicable) or is site selected without CDA in place.

CDA requested & reviewed. Feasibility form completed by team leader.

CDA should be drafted using standard wording with minimal changes.

Gov' team to consult with CRN (commercial studies) or PI (non-commercial) to assess if non-standard wording can be accepted.

Unable to reach agreement; EOI process stops.

CDA signed.

CRF to run study?

yes

Sponsor informed of CRF use.

FEASIBILITY STAGE

Study progresses; budget agreed in principle. Study team identified.

Checkpoint 3

Recruitment timeline established.

Draft contract agreed in principle.

Checkpoint 2

Support services & CRF clinic capacity confirmed in principle.

Unable to reach agreement in principle on standardised draft budget /contract; study paused.

CRF team will commence initial draft budget review process. RPH Gov' team to perform a cursory review of draft budget.

CRF team to plan patient pathway & share with the RPH Gov' team. CRF to draft Directorate Authorisations (DA's) and risk assessments at this stage.

RPH Gov' Team will have oversight & coordinate internal checks i.e., sending DAs to services, assisting with risk assessments & contacting support services, in conjunction with the CRF team.

Local CRF# given, study registered & site file created. Team leader informed.

Checkpoint 1

Protocol, PIS, IRAS form, draft budget & draft contract received.

Prequalifying Site Selection visit to review Feasibility of site (IF APPLICABLE)

continues

Sponsor decides to continue based on CDA &/ Feasibility.

Sponsor declines the site.

STOP
DO NOT PROGRESS UNTIL CONFIRMATION OF REGULATORY APPROVALS RECEIVED & CRF & RPH HAVE REACHED AGREEMENT IN PRINCIPLE OF DRAFT CONTRACT & BUDGET WITH CRO/ SPONSOR.

CRF team to review capacity & agree to proceed with study.

Site File created. EDGE profile created as recruiting / PIC site.

Monitoring process agreed.
Arrange team & investigator / sponsor meetings. Engage with clinical teams / directorates prior to RGPAS. Protocol reviewed & understood. Patient pathway & recruitment logistics agreed. Blinded / unblinded personnel identified. PI to attend RGPAS. Scientific Advice Board (SAB) application form drafted but not submitted. DAs sent to services. Support services contacted.

Checkpoint 4

RGPAS meeting

RGPAS declines study.

RGPAS Agree to proceed.

CRF delegate to attend. Decision to approach SAB / not and costs are confirmed. Decision to utilise local labs and costs are confirmed.

GOVERNANCE TEAM REQUESTS LOCAL INFORMATION PACK (ALL STUDIES). SETUP BEGINS.

Email sent to study team and PI to inform 80 / 62 clock to first patient recruited has begun.

Checkpoint 5

Study team commences Sponsor Green Light Activities.

PTO

SET UP STAGE

STUDY OPENING

STOP
DO NOT ARRANGE SIV.
DISCUSS WITH GOVERNANCE BEFORE BOOKING.

- CVs & GCP certificates checked.
- Actions from RGPAS checked.
- Directorate Authorisation sent & approvals received.
- LIP documents added to N Drive and Site File.
- Pharmacy approval received, plus costs.
- 2nd Risk assessment review prior to C&C.
- Study teams to arrange CRF visits as applicable. CRF added to delegation log.
- CRF form sent to SAB, if applicable.
- Clinic space confirmed.
- Protocol specific training completed.
- Final Review of LIP. Missing information requested.
- Pathology registration form completed.
- Patient pathways finalised.

Checkpoint 6
Contract & Budgets signed. PI/ Team leader asked to prepare for C&C.

Checkpoint 7
Trust Confirmation of Capacity & Capability notification issued.

- Add calendar reminders for invoicing requirements.
- Supporting services are paid for their work.
- Sponsor green light requirements completed.

Checkpoint 8
Handover meeting with study team held and recap invoicing & EDGE specifics.

Study team agree with Governance team the SIV may be booked.
SIV held with sponsor.

- Invoice for set-up fees.
- Costs loaded onto EDGE.
- Delegation log signed.
- Staff training held during SIV.

STOP
DO NOT UNDERTAKE RESEARCH ACTIVITIES PRIOR TO RECEIPT OF C&C AND SPONSOR GREEN LIGHT.

- 1st patient consented & recruited.
- EDGE updated with recruitment; key dates & study status is updated throughout study life.
- Quarterly /other Invoicing process starts.
- EDGE updated with first patient.
- Screening & first visit commences.

Key

Blue surround =
Sponsor action


Green surround =
Papworth Research Team
action

Red surround = R&D
Governance team action

Coloured Block
= milestone
action

Joint actions.
Responsibilities
dictated by colour
code.

Checkpoint = Team Leader &
/ PI informed of progress.

 = Email sent

Milestone – Do Not Progress Until All Other Actions
Have Been Completed

Document(s) to be
reviewed

Decision to
be made

End of Stage